期刊文献+

麻黄碱对K562/A02细胞MDR1、MRP、TopoⅡ和GST表达的影响 被引量:3

Effect of ephedrine on the expression of MDR1、MRP、TopoⅡand GST in K562/A02 Cells
原文传递
导出
摘要 目的:研究麻黄碱对K562/A02细胞株多药耐药性逆转的作用。方法:采用噻唑蓝(MTT)法检测麻黄碱的细胞毒作用;采用半定量逆转录聚合酶链反应(RT-PCR)和免疫印迹分别检测非细胞毒浓度的麻黄碱对K562/A02细胞MDR1、MRP、TopoⅡ以及GST表达的影响。结果:非细胞毒浓度的麻黄碱作用后,K562/A02细胞的MDR1及P-gp表达降低(P<0.01);而TopoⅡ、MRP、GST的表达无明显变化(P>0.05)。结论:麻黄碱能部分逆转K562/A02细胞的耐药性,其作用机制可能与下调K562/A02细胞MDR1的mRNA的表达,导致细胞膜上P-gp的表达量减少有关。 Objective: To explore the reversal effect of ephedrine on human multidrug resistance leukemic cell line K562/A02. Methods : MTT as- say was used to analyze the eytotoxicity of ephedrine; the semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western Blot were used to detect the mRNA and protein expressiom of MDR1, MRP, Topo Ⅱ , and GST gene of K562/A02 cells after treatment with non-cytotoxic concentration of ephedrine, respectively. Results : Ephedrine at non-cytotoxic concentration led to significant downregtdation of mRNA and p-glycoprotein expression of MDR1 gene in K562/A02 cells ( P 〈 0.01 ) , but little effect on the no the expression of MRP, Topo Ⅱ , and GST ( P 〉 0.05 ). Conclusion : Ephedrine partly reverse multidrug resistance of K562/A02 ceils through downregulating the expression of MDR1 mRNA, which may lead to the reduction of p-glycoprotein expression on celt membrane.
出处 《中药药理与临床》 CAS CSCD 北大核心 2009年第2期40-43,共4页 Pharmacology and Clinics of Chinese Materia Medica
基金 江苏省中医药管理局资助项目(H05110)
关键词 麻黄碱 K562/A02细胞 多药耐药 逆转 ephedrine K562/A02 muhidrug resistance reverse
  • 相关文献

参考文献9

二级参考文献61

  • 1陈勇川,高振同.哮喘合剂中盐酸麻黄碱的含量测定[J].药学实践杂志,2000,18(6):382-383. 被引量:1
  • 2陈宝安,钱习军,程坚,高峰.汉防己甲素联合屈洛昔芬对K562细胞bcr/abl表达的影响[J].中国实验血液学杂志,2005,13(1):95-99. 被引量:9
  • 3Dorigo O, Turla S T, Lebedeva S, et al. Sensitization of rat glioblastoma multiform to cisplatin in vivo following restoration of wild-type p53 function [J]. J Neurosurg, 1998,88(3):535-540.
  • 4Cole S P, Sparks K E, Fraser K, et al. Pharmacological characterization of multidrug resistance MRP-transfected human tumor cell [J]. Cancer Res, 1994,54(22):5902-5910.
  • 5Tew K D. Glutathione-associated enzymes in anticancer drug resistance [J]. Cancer Res, 1994,54(16) :4313-4320.
  • 6Pommier Y, Leteurtre F, Fesen M R, et al. Cellular determinations of sensitivity and resistance to DNA topoisomerase inhibitors [J]. Cancer Invest, 1994,12(5):530-542.
  • 7Wang L, Yang C P, Horwitz S B, et al. Reversal of the human murine multidrug-resistance phenotype with megestrol acetate [J]. Cancer Chemother Pharmcol, 1994,34(2) :96-102.
  • 8Tetu B, Bfisson J, Plante V, et al. p53 and c-erbB-2 as makers of resistance to adjuvant chemotherapy in breast cancer[J]. Mod Pathol, 1998,11 (9) : 823-830.
  • 9Linn S C, Honkoop A H, Hoekman K, et al. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer [ J ]. Br J Cancer, 1996,74 ( 1 ) : 63-68.
  • 10Fan S, el-Deiry W S, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents [J]. Cancer Res, 1994,54(22):5824-5830.

共引文献54

同被引文献120

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部